#USA #New York #Class Action #Securities Laws #Tenax Therapeutics

Tenax Therapeutics Class Action Update

In a significant development for investors of Tenax Therapeutics, Inc. (NASDAQ: TENX), Bronstein Gewirtz & Grossman, LLC has announced a class action lawsuit aimed at recouping losses attributed to alleged violations of federal securities laws. The firm is urging affected investors to come forward and be part of this collective action.

Background of the Lawsuit

The lawsuit targets individuals and entities that acquired Tenax securities during what is identified as the class period, which spans from November 13, 2023, to August 7, 2026. During this timeframe, the complaint alleges that the defendants made materially misleading and false statements regarding the efficacy of the company’s leading clinical program, TNX-103. This program, according to the complaint, was portrayed to be substantially more effective than it actually was, leading to grossly overstated expectations regarding its clinical and commercial viability.

Key Allegations:
1. The defendants allegedly misrepresented the effectiveness of TNX-103, which significantly misled investors.
2. False claims regarding the regulatory and commercial prospects of TNX-103 have also been made, thus inflating investor expectations without substantiated backing.
3. All public statements made during this period regarding the efficacy of the company’s leading product were found to be materially false and misleading.

Implications for Investors

For investors who believe they were impacted by these alleged violations, now is the time to act. The court has set a deadline of December 28, 2026, for investors wishing to be appointed lead plaintiff in this case. Those affected are encouraged to visit the firm’s dedicated web page for this case at bgandg.com/cases/tenax-therapeutics-inc-tenx-class-action-lawsuit to find out more about their potential eligibility to recover damages.

Costs and Representation

One of the significant appeals for potential plaintiffs is that Bronstein Gewirtz & Grossman LLC operates on a contingency fee basis. This means that investors do not have to worry about upfront legal fees; any costs incurred will only be claimed upon a successful recovery in this case. This model not only reduces the financial risk for individual investors but also reinforces the commitment of the firm to seek justice on behalf of those affected.

Why Choose Bronstein Gewirtz & Grossman?

The firm is well-regarded nationally for its representation of investors in securities fraud cases and shareholder derivative suits. Known for recovering substantial financial settlements for clients across the United States, the firm focuses on holding companies accountable for their actions and ensuring that investors are treated fairly within the marketplace. Peretz Bronstein, the founding partner, stated that the firm is dedicated to restoring capital for investors and upholding the integrity of the marketplace.

In conclusion, if you are an investor who engaged with Tenax Therapeutics' securities within the specified time frame, it is advisable to consider participation in this class action. Taking action now could lead to justice and recovery of misappropriated funds. For more updates and information, follow Bronstein Gewirtz & Grossman through their social media platforms or contact them directly at 917-590-0911.